A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
NCT02334735
Completed
Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides compared to Montanide® in study subjects with melanoma in complete clinical remission.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2022
Locations: New York University Langone Medical Center, New York, New York +1 locations
Conditions: Melanoma
Register for Updates
A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
NCT04168190
Completed
This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2022
Locations: Simon Williamson Clinic ( Site 0004), Birmingham, Alabama +19 locations
Conditions: Pneumonia, Pneumococcal
Register for Updates
Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years
NCT01676402
Completed
This is a Phase Ib study in healthy adults (18-70 years) to evaluate the safety, tolerability, and immunogenicity of same season and sequential season vaccination schedules consisting of the 2012/2013 seasonal influenza DNA vaccine (HA DNA) and licensed trivalent influenza vaccine (TIV) administered intradermally (ID) or intramuscularly (IM). The hypothesis is that evaluation of these investigational schedules will inform development of novel influenza vaccine strategies that may offer improved... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/22/2022
Locations: Stanford University School of Medicine, Stanford, California +3 locations
Conditions: Influenza
Register for Updates
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590
Completed
The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2 month schedule, in older adults aged 60 to 80 years. As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2022
Locations: GSK Investigational Site, Jacksonville, Florida +20 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
NCT00820846
Completed
The purpose of this study is to evaluate the safety of and immune response to a two-vaccine regimen in healthy, HIV-uninfected adults who have never received an HIV preventive vaccine before.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/04/2022
Locations: Alabama CRS, Birmingham, Alabama +11 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
NCT02852005
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens in the HVTN 205 study.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/04/2022
Locations: Alabama CRS, Birmingham, Alabama +8 locations
Conditions: HIV Infections
Register for Updates
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
NCT04798001
Unknown
This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose. Specifically, this study analyzes the safety of, and the immune response to, the vaccine when administered... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
08/01/2022
Locations: Johnson County Clin-Trials, Lenexa, Kansas +1 locations
Conditions: Covid19
Register for Updates
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Unknown
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Gender:
ALL
Ages:
Between 6 months and 36 months
Trial Updated:
08/01/2022
Locations: MedPharmics, Phoenix, Arizona +11 locations
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01673217
Completed
This phase I trial is studying the side effects and best dose of decitabine when given together with pegylated liposomal doxorubicin hydrochloride and vaccine therapy in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. Drugs used in chemotherapy, such as decitabine and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccin... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2022
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Register for Updates
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
NCT01808456
Completed
Influenza infection in recipients of solid organ transplants recipients while on maintenance immunosuppressant therapy is associated with increased morbidity and mortality. Although influenza vaccination is recommended in these high-risk patients, safety and immunogenicity of commercially available different strengths of influenza vaccine have not been established. The primary study objective is to determine the safety and immunogenicity of Fluzone and Fluzone High-Dose, with a secondary object... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/20/2022
Locations: Inova Fairfax Hospital, Falls Church, Virginia
Conditions: Influenza, Human, Transplantation Infection
Register for Updates
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
NCT01808820
Completed
The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.
Gender:
ALL
Ages:
Between 13 years and 99 years
Trial Updated:
07/19/2022
Locations: University of Miami, Miami, Florida
Conditions: Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Register for Updates
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
NCT03636906
Completed
The purpose of this study is to provide critical information on the safety, reactogenicity and immunogenicity profile of the investigational recombinant chimpanzee adenovirus Type 155-vectored RSV (ChAd155-RSV) vaccine in infants likely to be unexposed to RSV and will assess a single lower dose and a higher two dose regimen, before moving to future studies. This study will also assess if there is a risk of 'vaccine-induced enhanced RSV disease' after vaccination of these infants with the ChAd155... Read More
Gender:
ALL
Ages:
Between 6 months and 7 months
Trial Updated:
07/05/2022
Locations: GSK Investigational Site, Atlanta, Georgia +36 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates